A Phase 4 interventional study of Abilify(Aripiprazole) and Depakote(Divalproate) in Bipolar Disorder, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-06-25.
Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment
To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.
Further study details as provided by Korea OIAA
1,602 studies on the registry are indexed under Bipolar Disorder; 255 are open to participants now.
This study's planned enrollment of 280 is above the median of 64 across 1,223 interventional studies indexed under Bipolar Disorder.
Browse Bipolar Disorder studies →Korea Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Patients with the following clinical symptoms diagnosed using DSM-IV:
co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
Changes in the YMRS total score from baseline to the end of 6-week study
Time frame: Throughout the study
Changes in YMRS total scores from baseline to the end of 6-week study
Time frame: Throughout the study
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea Otsuka Pharmaceutical Co., Ltd.